Company database

Almac Discovery's current official pipeline lists an oral GSPT1 molecular glue and a GSPT1 degrader–antibody conjugate, both preclinical. DAC payloads are used in HER2/CD33-targeted constructs.

C

Catalent

Compare

Public service pages disclose mRNA/saRNA analysis, including IPRP-HPLC, RT-qPCR, cell-free potency assays, and LNP characterization. These disclosures do not establish full mRNA-LNP manufacturing at every site.

L

Lonza

Compare

Offers mRNA/LNP process and analytical development and clinical and small-scale commercial manufacturing. Geleen integrates RNA and LNP production.

E

Evonik

Compare

Evonik combines its lipid/LNP development services with ST PHARM's custom nucleic acid capabilities. A partnered supply chain does not mean Evonik manufactures every component itself.

TL

Triclinic Labs

Compare

A U.S. solid-state R&D and analytical CRO offering solid-form screening, structural characterization, and intellectual-property-related studies.

C

CureVac

Compare

BioNTech announced completion of its CureVac acquisition on 2025-12-18. This record retains CureVac's mRNA technology and historical entity information without treating it as an independent publicly traded company.

E

Ethris

Compare

Uses mRNA technology to develop respiratory treatments; official disclosures report 2022 financing and a strategic investment from Cipla.

E

etherna

Compare

Offers mRNA engineering, custom LNPs, and manufacturing technology platforms to support partners from design through production.

AB

Abogen Biosciences

Compare

Discloses an integrated mRNA/LNP platform. Its lyophilized shingles mRNA vaccine ABO1108 is in Phase 3 in China. The ABO2203 licensing and option agreement with Novartis announced on 2026-10-02 is not classified as financing.

V/

Veranova / Pharmorphix

Compare

The solid-state and physicochemical team offers early enabling formulation prototypes to support preclinical performance. This record does not claim comprehensive commercial drug product manufacturing capability.

WB

WestGene Biopharma

Compare

Founded in July 2021, the company focuses on innovative mRNA drugs and adjuvants, with oncology, infectious disease, and other mRNA programs.

R

RNACure

Compare

Founded in 2019, the company discloses mRNA molecular engineering, delivery, and immunomodulation platforms with CMC integrated into technology development.

I

Innorna

Compare

IN006 is a bivalent RSV vaccine based on the company's mRNA and LNP platforms. The company reported completion of Phase 2 enrollment and vaccination in 2025; IN026 received FDA IND clearance in 2026.

M

MediciBIO

Compare

Develops gene delivery platforms for mRNA, saRNA, siRNA, and ASOs, along with internal drug programs. In 2026 it announced an LNP platform and Korean-market collaboration with Crystal NAX.

A

Ardena

Compare

Offers formulation, analytical testing, GMP clinical batches, and stability studies for oral solids, sterile injectables, and complex products including nanomedicines.

S

Solvias

Compare

A contract provider focused on solid-state and particle characterization and analytical development for small-molecule drugs. Historical directory descriptions are not treated as evidence of a current comprehensive screening service.

A

Almac

Compare

Original technical materials describe macrocycle, stapled peptide, and bicyclic peptide synthesis. Included as discovery / manufacturing services, not elevated to an oral clinical drug developer.

RT

ReCode Therapeutics

Compare

Develops mRNA and gene correction therapies using tissue-selective LNP delivery. In 2026 it disclosed additional Cystic Fibrosis Foundation support and a cystic fibrosis gene-editing collaboration.

CT

Cartesian Therapeutics

Compare

Develops mRNA cell therapies, with a lead program based on ex vivo mRNA CAR-T. It also collaborates with WestGene on in vivo tLNP delivery; these approaches should be evaluated separately.

RB

Replicate Bioscience

Compare

A clinical-stage self-replicating RNA technology developer spanning infectious diseases, immunology, and other therapeutic areas.

TB

Tiba Biotech

Compare

Develops RNA nanodelivery through a non-lipid approach adjacent to LNP technology; it should not be classified as a conventional LNP platform.

Z

Ziphius

Compare

Founded in 2019, the company develops self-amplifying RNA vaccines and therapeutics and LNP platforms.

ES

ELDICO Scientific

Compare

Sells ED-1 instruments and operates the ED-CRO sample submission structure determination service. The commercial service has been separately confirmed for this record.

A

Aldevron

Compare

Offers RNA drug substance, LNP encapsulation, analytical testing, and aseptic fill-finish, with disclosed mRNA-LNP manufacturing in one facility under one quality system.